T

Texas Clinical Research Institute | Arlington, TX

Research site
(Unclaimed)
Location
1009 Magnolia Street, Arlington, Texas, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

12 of 80
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis (ELFIDENCE)

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC).Participants will also have inadequate response or intolerance t...

Enrolling
Primary Biliary Cholangitis (PBC)
Other: Matched 80 mg placebo
Drug: Elafibranor

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Enrolling
NASH
Cirrhosis, Liver
Drug: Resmetirom
Drug: Placebo

This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as mainten...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: ABX464

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinica...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: ABX464

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely...

Enrolling
Ulcerative Colitis
Drug: Etrasimod

A phase 2b, multicenter, randomized, double-blind, placebo-controlled study of HTD1801 in adult subjects with non-alcoholic steatohepatitis and liver...

Active, not recruiting
Nonalcoholic Steatohepatitis (NASH)
Type 2 Diabetes
Drug: Placebo
Drug: HTD1801

The purpose of this study is to compare PL8177 (a melanocortin receptor agonist) to placebo (in a 3:1 ratio-meaning that for every 3 people that get...

Enrolling
Ulcerative Colitis Flare
Ulcerative
Drug: PL8177 Placebo
Drug: PL8177

This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (stea...

Enrolling
Non Alcoholic Steatohepatitis (NASH)
Drug: AXA1125
Drug: Placebo

This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study will assess the effi...

Active, not recruiting
Cirrhosis
Prevention of Esophageal Varices
Drug: belapectin
Drug: Placebo

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid...

Active, not recruiting
Primary Biliary Cirrhosis
Drug: Elafibranor 80mg
Drug: Placebo

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting
Nonalcoholic Steatohepatitis
Drug: PTM CILO/FIR
Drug: Cilofexor (CILO)/Firsocostat (FIR)

Trial conditions

Fatty Liver (29 trials)
Non-alcoholic Fatty Live... (29 trials)
Hepatitis C (17 trials)
Fibrosis (16 trials)
Hepatitis (15 trials)
Liver Cirrhosis (13 trials)
Hepatitis A (11 trials)
Crohn Disease (10 trials)
Chronic Hepatitis C (9 trials)
Colitis (8 trials)

And 22 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems